Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.
The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.
Consolidation within the industry also remained brisk as cost and reimbursement concerns provided acquisition opportunities for large national outfits.
Top Five Articles on 360Dx Last Week: Labcorp Asset Acquisition, Roche CE Mark for Mass Spec, More Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback